AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21177789 — intervention group
Group type: EXPERIMENTAL
Intervention: NNC126‐0083
Number of subjects: 33
Study 19856792 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg) - Itopride (150 mg) fixed dose combination (FDC)
Number of subjects: 12
Study 19856792 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 12
Study 17664232 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR neuropsychological battery and Cognitive Symptoms Inventory (CSI)
Number of subjects: 0
Study 12571611 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg b.i.d.
Number of subjects: 0
Study 12571611 — intervention group
Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 0
Study 11140307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 0
Study 8863009 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar free diet for six months
Number of subjects: 32
Study 8863009 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 32
Study 1710669 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment program for pain control
Number of subjects: 39
Study 1710669 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 39
Study 6367859 — intervention group
Group type: EXPERIMENTAL
Intervention: Five drugs (CMFVP)
Number of subjects: 772
Study 6367859 — intervention group
Group type: COMPARATOR
Intervention: Three drugs (CMF)
Number of subjects: 772
Study 6367859 — intervention group
Group type: EXPERIMENTAL
Intervention: Two scheduling methods of CMFVP
Number of subjects: 772
Study 6367859 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cross-reacting drug combination
Number of subjects: 772
Study 4009829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled drainage
Number of subjects: 31
Study 4009829 — intervention group
Group type: COMPARATOR
Intervention: Suction drainage
Number of subjects: 31
Study 29411270 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E softgel (300 mg/day)
Number of subjects: 120
Study 29411270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 27874885 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid (AzA) 15% foam
Number of subjects: 961
Study 27874885 — intervention group
Group type: COMPARATOR
Intervention: Vehicle foam (control)
Number of subjects: 961
Study 24421213 — intervention group
Group type: EXPERIMENTAL
Intervention: Praise
Number of subjects: 59
Study 24421213 — intervention group
Group type: COMPARATOR
Intervention: Criticism
Number of subjects: 59
Study 23242728 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide vaginal suppositories
Number of subjects: 50
Study 23242728 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine digluconate vaginal suppositories
Number of subjects: 50
Study 20728066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg morphine plus 5mg ketamine/bolus (group MK)
Number of subjects: 46
Study 20728066 — intervention group
Group type: COMPARATOR
Intervention: 2mg/bolus morphine (group MO)
Number of subjects: 46
Study 18093117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led clinic
Number of subjects: 43
Study 18093117 — intervention group
Group type: COMPARATOR
Intervention: Medical on-treatment review
Number of subjects: 43
Study 16963789 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen in air (Group A)
Number of subjects: 377
Study 16963789 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen in air (Group B)
Number of subjects: 377
Study 16963789 — intervention group
Group type: COMPARATOR
Intervention: 40% oxygen in nitrous oxide (Group C)
Number of subjects: 377
Study 14580054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 1.8 mg kg(‐1)
Number of subjects: 150
Study 14580054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.15 mg kg(‐1)
Number of subjects: 150
Study 14580054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 10957848 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 28
Study 8827968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ingestion at a fixed rate
Number of subjects: 7
Study 8827968 — intervention group
Group type: COMPARATOR
Intervention: Blinded comparison of blood samples
Number of subjects: 7
Study 1487094 — intervention group
Group type: EXPERIMENTAL
Intervention: Five most apical electrodes eliminated from the subject's MAP
Number of subjects: 5
Study 1487094 — intervention group
Group type: EXPERIMENTAL
Intervention: Five most basal electrodes eliminated from subject's MAP
Number of subjects: 5
Study 1487094 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle five electrodes eliminated from subject's MAP
Number of subjects: 5
Study 1487094 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject's current MAP
Number of subjects: 5
Study 6152616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl at 3 micrograms kg‐1 h‐1 with 66% N2O
Number of subjects: 16
Study 6152616 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone
Number of subjects: 16
Study 6152616 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil at 20 micrograms kg‐1 h‐1 with 66% N2O
Number of subjects: 16
Study 6152616 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 16
Study 31149930 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin alone (150 mg preoperatively and twice daily for 14 days)
Number of subjects: 150
Study 29566463 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly supervised physical training sessions in a fitness center
Number of subjects: 60
Study 29566463 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 60
Study 26671006 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous testosterone
Number of subjects: 0
Study 26671006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24834892 — intervention group
Group type: EXPERIMENTAL
Intervention: SpS-SubmSv IRT
Number of subjects: 10
Study 24834892 — intervention group
Group type: COMPARATOR
Intervention: SubmSv-FBP
Number of subjects: 10
Study 24834892 — intervention group
Group type: COMPARATOR
Intervention: SD-FBP
Number of subjects: 10
Study 23154549 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostatin treatment (paclitaxel + carboplatin + endostatin)
Number of subjects: 122
Study 23154549 — intervention group
Group type: COMPARATOR
Intervention: Control group (paclitaxel + carboplatin + placebo)
Number of subjects: 122
Study 19937362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg)
Number of subjects: 70
Study 19937362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus Metformin (15 mg + 1,700 mg)
Number of subjects: 70
Study 19114406 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal (200 g boiled white rice with 50 g natto, 60 g Japanese yams, and 40 g okras)
Number of subjects: 11
Study 19114406 — intervention group
Group type: COMPARATOR
Intervention: Control meal (200 g white rice with non-viscous boiled soybeans, potatoes, and broccoli)
Number of subjects: 11
Study 19114406 — intervention group
Group type: COMPARATOR
Intervention: Test meal vs Control meal
Number of subjects: 11
Study 16117996 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 100
Study 16117996 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 100
Study 12530340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (daily dosing)
Number of subjects: 18
Study 12530340 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (twice daily dosing)
Number of subjects: 18
Study 10587025 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop excision
Number of subjects: 240
Study 10587025 — intervention group
Group type: COMPARATOR
Intervention: Cold knife conization
Number of subjects: 240
Study 8905434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsating low air‐loss bed
Number of subjects: 16
Study 8905434 — intervention group
Group type: COMPARATOR
Intervention: Standard non‐pulsating bed
Number of subjects: 16
Study 1860008 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg/24 h, increased to 100 mg/24 h after 16 months, thiazide added after 30 months)
Number of subjects: 44
Study 1860008 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 44
Study 6225482 — intervention group
Group type: EXPERIMENTAL
Intervention: spectinomycin 2 g intramuscularly (group A)
Number of subjects: 400
Study 6225482 — intervention group
Group type: EXPERIMENTAL
Intervention: cefamandole 1 g intramuscularly after probenecid 1 g orally (group B)
Number of subjects: 400
Study 6225482 — intervention group
Group type: EXPERIMENTAL
Intervention: cefaclor 3 g orally with probenecid 1 g orally (group C)
Number of subjects: 400
Study 6225482 — intervention group
Group type: EXPERIMENTAL
Intervention: cefaclor 3 g orally (group D)
Number of subjects: 400
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequately treated risk conditions
Number of subjects: 1730
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequately treated risk conditions including lifestyle risk behaviors
Number of subjects: 1730
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor control in recurrent events vs first-ever events
Number of subjects: 1730
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor control in men vs women
Number of subjects: 1730
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor control in patients ≤75 vs >75 years of age
Number of subjects: 1730
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated degree of stroke preventability for individual risk factors
Number of subjects: 1730
Study 31672716 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate control of the 5 most relevant risk factors combined
Number of subjects: 1730
Study 28119329 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker chromosomes in patients with adverse-risk karyotypes
Number of subjects: 1026
Study 28119329 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker chromosomes presence
Number of subjects: 1026
Study 28119329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromothripsis-positive cases
Number of subjects: 1026
Study 28119329 — intervention group
Group type: COMPARATOR
Intervention: Control group of marker chromosome-negative complex aberrant karyotypes
Number of subjects: 1026
Study 25828362 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 1 × 3 mg/kg on Day 1
Number of subjects: 100
Study 25828362 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 1 × 10 mg/kg on Day 1
Number of subjects: 100
Study 25828362 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 3 × 10 mg/kg on Days 1, 15 and 29
Number of subjects: 100
Study 25828362 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 23560618 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO measurement in athletes
Number of subjects: 87
Study 23560618 — intervention group
Group type: COMPARATOR
Intervention: FENO measurement in sedentary patients
Number of subjects: 87
Study 21976574 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass distribution of azithromycin (MDA)
Number of subjects: 1036
Study 21976574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MDA)
Number of subjects: 1036
Study 19487593 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 microg/mm2)
Number of subjects: 131
Study 19487593 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 131
Study 19487593 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 131
Study 17372773 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 10 microg/kg
Number of subjects: 18
Study 17372773 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 18
Study 15050487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (n = 207)
Number of subjects: 418
Study 15050487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 418
Study 15050487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 418
Study 11734596 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 620
Study 11734596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen and progestin use
Number of subjects: 620
Study 11734596 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed estrogen use
Number of subjects: 620
Study 8995082 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted right hemicolectomy (LARHC)
Number of subjects: 61
Study 8995082 — intervention group
Group type: COMPARATOR
Intervention: Open right hemicolectomy (ORHC)
Number of subjects: 61
Study 8496512 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional programme for self-management of asthma
Number of subjects: 23
Study 3440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (0.7 mg kg‐1 and 1.4 mg kg‐1)
Number of subjects: 6
Study 3440093 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine (0.3 mg kg‐1 and 0.6 mg kg‐1)
Number of subjects: 6
Study 3440093 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 29927893 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw-repositioning custom-made mouthguard (JCM)
Number of subjects: 0
Study 29581218 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 1403
Study 25178454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal temperature (Toes)
Number of subjects: 8
Study 25178454 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastro-intestinal tract temperature (Tgi)
Number of subjects: 8
Study 25178454 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature (Trec)
Number of subjects: 8
Study 25546163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention
Number of subjects: 428
Study 25546163 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 428
Study 24011093 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation delivered by a Teenage Cancer Trust educator in Autumn 2013 (intervention group)
Number of subjects: 20
Study 24011093 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving the presentation in Spring 2014 after six-month follow-up measures
Number of subjects: 20
Study 24011093 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 20
Study 24011093 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 21349890 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve (n = 141; 8 subclavian and 133 transfemoral)
Number of subjects: 328
Study 21349890 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien (n = 187; 99 transfemoral and 88 transapical)
Number of subjects: 328
Study 19153868 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy learning
Number of subjects: 27
Study 19153868 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit learning
Number of subjects: 27
Study 19153868 — intervention group
Group type: COMPARATOR
Intervention: Control (no instruction)
Number of subjects: 27
Study 17408662 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 503034 200 mg plus PEG‐IFN‐alpha‐2b
Number of subjects: 26
Study 17408662 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 503034 400 mg plus PEG‐IFN‐alpha‐2b
Number of subjects: 26
Study 17408662 — intervention group
Group type: COMPARATOR
Intervention: SCH 503034 200 mg alone
Number of subjects: 26
Study 17408662 — intervention group
Group type: COMPARATOR
Intervention: SCH 503034 400 mg alone
Number of subjects: 26
Study 17408662 — intervention group
Group type: COMPARATOR
Intervention: PEG‐IFN‐alpha‐2b alone
Number of subjects: 26
Study 15570081 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MPH (0.3 mg/kg; maximum dose, 10 mg bid)
Number of subjects: 83
Study 15570081 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose MPH (0.6 mg/kg; maximum dose, 20 mg bid)
Number of subjects: 83
Study 15570081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 15570081 — intervention group
Group type: EXPERIMENTAL
Intervention: Best clinical management
Number of subjects: 83
Study 11257278 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower plasma bilirubin levels in males (12.5 micromol/l)
Number of subjects: 328
Study 11257278 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum albumin and lower HDL-C
Number of subjects: 328
Study 11257278 — intervention group
Group type: EXPERIMENTAL
Intervention: Major gene segregation of bilirubin levels
Number of subjects: 328
Study 11257278 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased bilirubin levels
Number of subjects: 328
Study 11257278 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse correlation between HDL-C and bilirubin
Number of subjects: 328
Study 9449146 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity-counseling skills training
Number of subjects: 11
Study 9449146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 11
Study 8852539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4-6 mg once daily)
Number of subjects: 3660
Study 8852539 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 3660
Study 8852539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg, titrated to 25 mg if required)
Number of subjects: 3660
Study 2242077 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg temazepam
Number of subjects: 201
Study 2242077 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg temazepam
Number of subjects: 201
Study 2242077 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg temazepam
Number of subjects: 201
Study 2242077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of temazepam
Number of subjects: 201
Study 2242077 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (all doses)
Number of subjects: 201
Study 2242077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 346260 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 51
Study 346260 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 51
Study 346260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 31965772 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg thrice daily for 1 week
Number of subjects: 30
Study 31965772 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir 500 mg
Number of subjects: 30
Study 28056794 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercury concentration in toenails (μg per gram)
Number of subjects: 7477
Study 28056794 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest versus lowest quartile of mercury concentration
Number of subjects: 7477
Study 28056794 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest versus lowest quartile of mercury concentration within the Mediterranean diet intervention group
Number of subjects: 7477
Study 28056794 — intervention group
Group type: COMPARATOR
Intervention: Highest versus lowest quartile of mercury concentration within the control arm of the trial
Number of subjects: 7477
Study 28056794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption and n-3 fatty acids
Number of subjects: 7477
Study 25825853 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) with polyethylene glycol
Number of subjects: 44
Study 25825853 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (No MBP)
Number of subjects: 44
Study 26442364 — intervention group
Group type: EXPERIMENTAL
Intervention: eSMART‐HD (serious game for health)
Number of subjects: 116
Study 26442364 — intervention group
Group type: COMPARATOR
Intervention: Screen-based HTN education (attentional control)
Number of subjects: 116
Study 23497163 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching with motivational interviewing and a wide range of activities
Number of subjects: 0
Study 23497163 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching
Number of subjects: 0
Study 20624812 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course intravenous antibiotic treatment (≤3 days)
Number of subjects: 12333
Study 20624812 — intervention group
Group type: COMPARATOR
Intervention: Long-course intravenous antibiotic treatment (≥4 days)
Number of subjects: 12333
Study 18468748 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor plus ARB
Number of subjects: 425
Study 17000967 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 46
Study 17000967 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 46
Study 12853381 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor therapy
Number of subjects: 40
Study 10928765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporine emulsion
Number of subjects: 31
Study 10928765 — intervention group
Group type: COMPARATOR
Intervention: 0.1% cyclosporine emulsion
Number of subjects: 31
Study 10928765 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 31
Study 9481968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms fentanyl citrate via periodontal ligament injection
Number of subjects: 20
Study 9481968 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo via periodontal ligament injection
Number of subjects: 20
Study 7942261 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T380A IUD
Number of subjects: 0
Study 7942261 — intervention group
Group type: COMPARATOR
Intervention: Multiload Cu250 IUD
Number of subjects: 0
Study 3357006 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (VCR, 1.5 mg/m2 IV days 1 and 8; CYC, 275 mg/m2 IV days 1 through 5; ACT‐D, 0.45 mg/m2 IV days 1 through 5 every 28 days for three cycles)
Number of subjects: 70